ASPiRATION Recruitment Complete

An observational cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patients

As of 22nd of June 2023 TOGA are pleased to announce that we have enrolled 1,000 patients to The ASPiRATION study and completed our recruitment target. While recruitment to the study is now closed, the ASPiRATION substudies will remain open to eligible patients screened through MoST or CaSP.

TOGA has long recognised the importance of improved genetic testing in patient care to deliver personalised medicine, and together with Omico and the NHMRC Clinical Trials Centre of The University of Sydney established a national multicentre study in 2020: ASPiRATION, an observational cohort study to assess the clinical impact of upfront comprehensive genomic profiling (CGP) on the management of patients with metastatic NSCLC. As well as generating important clinical data, ASPiRATION enabled access to testing for hundreds of genetic variants in a single test for newly diagnosed metastatic NSCLC patients. If an actionable genetic variant was identified, the patient was offered options to access targeted treatments, such as a clinical trial. 

ASPiRATION is a collaborative program led by the Thoracic Oncology Group of Australasia (TOGA), in collaboration with Omico (Australian Genomic Cancer Medicine Centre) and the NHMRC Clinical Trials Centre (CTC) of The University of Sydney, and we would like to thank each for their efforts and contributions.

The program has been supported by funding from the federal government’s Medical Research Future Fund (MRFF) and Roche Products Australia, who we thank for making this program possible.

Finally, the ASPiRATION study team would like to sincerely thank the trial participants, study sites and clinicians for their hard work and contributions that allowed us to reach this significant milestone.

How can mNSCLC patients access molecular screening from here?

ASPiRATION Recruitment Complete

Now that recruitment has closed, any patients who would have been eligible for ASPiRATION will be able to access CGP and the ASPiRATION substudies via Omico’s new program CaSP (Cancer Screening Program).

CaSP differs from ASPiRATION in that there are no study sites, and all screening will occur centrally through Omico via referral for remote consent. With CaSP the expected turnaround time is 8-10 weeks.

The CaSP referral form can be accessed via the following link: CaSP Referral Form

Further information about CaSP is available here via the Omico website, or contact